At Xoft, we are building the future of radiation oncology.

Our Axxent^® Electronic Brachytherapy System^® uses proprietary, miniaturized X-ray tube technology to apply radiation directly to the target. Without radioactive isotopes, heavy shielding, or major capital investment, the Axxent platform delivers cost-effective results for an expanding list of indications.

Currently, the Axxent System has FDA clearance for accelerated treatment of early stage breast cancer and for treatment of endometrial cancer. The system is a flexible, efficient, high-throughput platform. There’s no bunker to build, no radioactive isotopes to track or discard. Precision delivery minimizes the risk of radiation exposure to healthy tissue while reducing the number of required treatments. And with each new indication, the value grows.